Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Finished

HEPARANIB Small molecule heparanase inhibitors as anti-metastatic cancer drugs

Coordinator
Universiteit Leiden, Netherlands
Runs
1 June 2023 to 30 November 2024
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101111870

What the project is doing

In the project's own words, from its summary on CORDIS.

The Heparanib Proof-of-Concept project aims to establish the feasibility of our unique small molecule heparanase inhibitors as drug candidates for the treatment of metastatic cancers. To strengthen our science case (experimental development A) and by building on our in vivo data in mouse models for metastatic breast cancer, lung cancer and multiple myeloma, we will (A-I) design a suitable route of synthesis to prepare sufficient quantities of clinical grade material; (A-II) synthesise reference compounds; and (A-III) perform initial pharmacokinetics/pharmacodynamics (PK/PD) studies.

With the aim to prepare for the establishment of a spin-out biotech company (business development B) to take our leads towards the clinic we will (B-IV) strengthen our intellectual property (IP) position; (B-V) perform an extensive analysis of the anti-metastatic cancer drug market; and (B-VI) prepare for commercialisation by consolidating the results in an investor-ready business plan to develop and commercialise our anticancer drug candidate.

Topics

Who is involved

OrganisationCityCountryRole
Universiteit LeidenLeidenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI